Two-Drug combo aims to boost myeloma treatment
NCT ID NCT05002816
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 33 times
Summary
This study tests whether combining two approved multiple myeloma drugs, belantamab mafodotin and elotuzumab, is safe and works better together. It involves 24 adults whose cancer has returned or not responded after at least three prior treatments. The goal is to find the best dose and see how well the combination controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale New Haven Hospital
New Haven, Connecticut, 06512, United States
Conditions
Explore the condition pages connected to this study.